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Abstract
Background Sleep disorders can occur in early Parkinson’s disease (PD). However, the relationship between different sleep 
disturbances and their longitudinal evolution has not been fully explored.
Objective To describe the frequency, coexistence, and longitudinal change in excessive daytime sleepiness (EDS), insomnia, 
and probable REM sleep behavior disorder (pRBD) in early PD.
Methods Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI). EDS, insomnia, and pRBD were 
defined using the Epworth Sleepiness Scale, MDS-UPDRS Part I sub-item 1.7, and RBD screening questionnaire.
Results 218 PD subjects and 102 controls completed 5 years of follow-up. At baseline, 69 (31.7%) PD subjects reported 
one type of sleep disturbance, 25 (11.5%) reported two types of sleep disturbances, and three (1.4%) reported all three types 
of sleep disturbances. At 5 years, the number of PD subjects reporting one, two, and three types of sleep disturbances was 
85 (39.0%), 51 (23.4%), and 16 (7.3%), respectively. Only 41(18.8%) patients were taking sleep medications. The largest 
increase in frequency was seen in insomnia (44.5%), followed by EDS (32.1%) and pRBD (31.2%). Insomnia was the most 
common sleep problem at any time over the 5-year follow-up. The frequency of sleep disturbances in HCs remained stable.
Conclusions There is a progressive increase in the frequency of sleep disturbances in PD, with the number of subjects 
reporting multiple sleep disturbances increasing over time. Relatively a few patients reported multiple sleep disturbances, 
suggesting that they can have different pathogenesis. A large number of patients were not treated for their sleep disturbances.
Keywords Parkinson’s disease · Sleep · Insomnia · RBD · EDS · PPMI
Introduction
Sleep disturbances are common in Parkinson’s Disease 
(PD) and are recognized to be present in the early stages 
of disease [1]. A broad range of sleep disorders are seen 
[1] with potential interactions existing between the differ-
ent disorders. However, the relationship between these sleep 
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disturbances remains to be fully investigated, as they have 
mostly been studied in isolation, in the context of a broad 
range of non-motor symptoms, in cross-sectional or in short-
longitudinal cohorts.
Previously, a cross-sectional study by Suzuki and col-
leagues had investigated excessive daytime sleepiness 
(EDS), probable REM sleep behavior disorder (pRBD), and 
other PD-related sleep problems defined using the PD sleep 
scale (PDSS-2) in a cross-sectional cohort of PD patients in 
advanced disease. In that cohort, 20% of patients reported 
two types of sleep disturbances and 12.5% reported all three 
types of sleep disturbances, with significant overlap identi-
fied in the three sleep-related symptoms [2]. However, the 
PDSS-2 questionnaire itself has components with overlap 
with the reporting of EDS and pRBD, and does not allow 
the complaints of insomnia to be studied separately. Further-
more, it is unknown whether overlap observed between these 
commonly reported sleep-related symptoms in advanced dis-
ease is also observed in early PD.
The aim of this study was to examine the frequency, coex-
istence, and longitudinal changes over a 5-year period of 
the commonly reported sleep disturbances of EDS, insom-
nia, and pRBD in a large cohort of initially drug-naïve PD 
subjects. EDS, insomnia, and pRBD were defined using 
validated questionnaires to capture the patients’ subjective 
sleep complaints as reported in clinical settings. Findings 
were compared with healthy controls (HCs). The long dura-
tion of follow-up will help better understand the emergence 
and the relationship of the various sleep disturbances in early 
PD.
Methods
Study population
PD subjects and the HCs were identified from the Parkin-
son’s Progression Markers (PPMI) Initiative database. The 
PPMI is an ongoing longitudinal, multicentre observational 
clinical study of early PD patients with a clinical disease 
duration of less than 2 years who were initially treatment 
naïve. The diagnosis of PD had to be supported by in vivo 
evidence of nigrostriatal dopaminergic dysfunction by DAT 
SPECT. Control subjects recruited into the study had to be 
30 years or older and not to have a first degree relative diag-
nosed with PD. The full list of inclusion and exclusion cri-
teria can be found at the PPMI website (https ://www.ppmi-
info.org/). Each study site obtained local ethical approval.
For our analysis, we identified PD subjects in the PPMI 
database who had completed 5 years of follow-up. For these 
subjects, we downloaded baseline assessments and annual 
follow-up visits. When follow-up evaluations were unavaila-
ble, results were obtained from evaluations performed in the 
preceding or successive 6-month period. Since most patients 
started anti-parkinsonian medications between baseline and 
2 years, we decided to perform the first follow-up evaluation 
relative to 2 years.
We also extracted data from HCs recruited in the PPMI 
study with 5-year follow-up. The RBD Screening Question-
naire (RBDSQ) was one of the battery of tests performed 
to characterize both PD subjects and HCs after inclusion 
into the PPMI study. As the presence of REM sleep behav-
ior disorder (RBD) is now known to be strongly associated 
with future neurodegeneration, HCs who screened positive 
for RBD at any time point during this 5-year period were 
excluded from further analyses in our study.
Data were downloaded on 2nd November 2017.
Demographics and assessments:
The sleep disturbances evaluated include EDS, insomnia, 
and RBD. EDS was evaluated using the Epworth Sleepi-
ness Scale [3] where subjects self-report their likelihood of 
falling asleep in the preceding month with scores of ≥ 10 
indicating EDS [4].
Insomnia complaints were evaluated using sub-item 1.7 
of the Movement Disorders Society-Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS) [5]. Participants were 
asked: “Over the past week, have you had trouble going to 
sleep at night or staying asleep throughout the night? Con-
sider how rested you felt after waking up in the morning.” 
Clinically relevant insomnia was defined as a MDS-UPDRS 
sub-item 1.7 score ≥ 2, which was previously used [6] and 
shown to have good correlation with other insomnia rating 
scales [7]. The presence of RBD was assessed using the 
RBDSQ [8]. Subjects were classified as positive for RBD if 
they scored > 5 [9]. However, since RBD was not confirmed 
by polysomnography, we have used the term probable RBD 
(pRBD) in this study.
Demographic and clinical data including PD medication 
and sleep-related medication use were obtained from the 
medication logs. The total daily Levodopa equivalent daily 
dose (LEDD) was calculated using the established methods 
[10]. Clinical motor assessments performed included the 
Hoehn and Yahr (H&Y) stage [11] and the MDS-UPDRS 
Part III [5]. Cognition was evaluated using the Montreal 
Cognitive Assessment (MOCA) [12].
Statistical analysis was performed using SPSS Version 
24 for Windows (Armonk, NY:IBM Corp). Baseline demo-
graphics and clinical characteristics were compared between 
PD and HC groups using Chi-square or Fisher’s exact test for 
categorical variables and two-sample test and Mann–Whit-
ney U test for continuous variables. Similar statistical tests 
were conducted to compare PD subjects with no sleep dis-
turbance and at least one sleep disturbance.
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The number of PD patients reporting multiple types of 
sleep disturbances (two and three) increased over 5 years. 
We selected data at the 5-year mark to investigate the associ-
ation between demographics and clinical features (including 
age, LEDD, medication class of levodopa replacement ther-
apy used, and MDS-UPDRS Part III scores) and number of 
reported sleep disturbances (none, one, two, or three) using 
Chi-Square or Fisher’s exact test and analysis of variance 
and Kruskal–Wallis test for categorical and continuous vari-
ables, respectively. Post hoc pairwise comparisons (versus 
“No reported sleep disturbance” group as reference) were 
made using two-sided two-sample t test and Mann–Whit-
ney test for continuous variables and Chi-square or Fisher’s 
exact test for categorical variables. Similarly, the association 
between demographics and clinical variables PD subjects 
with no reported sleep disturbances, insomnia only, pRBD 
only, and EDS only at 5 years were also explored using the 
above-mentioned statistical methods. Bonferroni adjustment 
was used to correct for multiple testing. Statistical signifi-
cance level was set at < 0.05.
Results
Analysis of PPMI database and subject 
characteristics:
Baseline clinical assessments were available for 423 PD sub-
jects. Out of which, 218 completed both baseline and 5-year 
follow-up and were included in the analysis, although some 
had missing data for intermediate assessments. Therefore, 
we had 202 subjects who completed evaluations for 2-year 
follow-up, 211 for 3-year follow-up, and 210 for 4-year fol-
low-up. The clinical characteristics of these patients, except 
for disease duration, were not statistically different from 
those of the 205 patients excluded for the lack of 5-year 
follow-up (Supplementary Table 1).
Out of 196 HCs with available baseline clinical assess-
ments, 127 had completed evaluations at 5 years. Of those, 
25 HCs were excluded as their RBDSQ scores would suggest 
the presence of pRBD. In total, 102 HCs were included: 100 
had evaluations for 2-year follow-up and 98 had evaluations 
for 3-year and 4-year follow-ups.
Except gender distribution (PD group had a higher pro-
portion of male subjects compared to the HC group: 69% vs 
57%, p = 0.05), PD subjects and HCs were comparable in 
terms of baseline demographic variables and use of sleep-
related medications. The mean LEDD was 282 ± 233 mg, 
397 ± 294 mg, 498 ± 289 mg, and 585 ± 3 36 mg at the 2-, 
3-, 4-, and 5-year time points, respectively (Table 1).
At baseline, 16 (7.3%) PD subjects were using medica-
tions for sleep which increased to 41 (18.8%) PD subjects 
after 5 years (full details in Supplementary Table 2). In 
contrast, nine (8.9%) HCs were using medications for sleep 
at baseline which increased to 12 (11.8%) after 5 years.
Frequency of individual sleep disturbances 
over the 5‑year period
Insomnia was the most common sleep problem reported by 
our PD patients at any assessment over the 5-year follow-
up, followed by pRBD, and EDS. The comparison between 
PD patients and HCs showed that the proportion of PD 
and HCs reporting insomnia was not statistically different 
at baseline and 2-year time points. However, significantly 
more PD subjects reported insomnia compared to controls 
at years 3, 4, and 5 (Table 2). Similarly, the proportion of 
PD and HCs reporting EDS was not statistically different at 
baseline (p = 0.06), but a significantly higher proportion of 
PD subjects (compared to HCs) reported EDS at all other 
time points (p < 0.05) (Table 2).
Changes in the frequency of individual sleep 
disturbances over the 5‑year period
In PD patients, the largest increase in frequency over 5 years 
was seen with insomnia, followed by EDS and then pRBD 
(Table 2).
At baseline, 45 (20.6%) PD subjects reported insom-
nia which increased to 97 (44.5%) at 5 years (p < 0.001). 
At baseline, 37 (17.0%) PD subjects reported EDS which 
increased to 70 (32.1%) at 5 years (p < 0.001). At baseline, 
46 (21.1%) PD subjects reported pRBD, which increased to 
68 (31.2%) at 5 years (p = 0.005). In HCs, insomnia and EDS 
did not change significantly over time (Table 2). At baseline, 
15 (14.7%) HCs reported insomnia which increased to 18 
(17.7%) at 5 years (p = 0.405). At baseline, nine (8.8%) HCs 
reported EDS which increased to ten (9.8%) after 5 years 
(p = 0.763) (Table 2).
Coexistence of sleep disturbances in individual 
subjects
The percentage of PD subjects reporting multiple sleep dis-
turbances increased over time, but this was not the case in 
the HCs (Fig. 1). 
PD subjects
At baseline, 121 (55.5%) PD patients did not report any 
sleep disturbances. Sixty-nine (31.7%) PD patients reported 
one type of sleep disturbance: 28 (12.8%) reported insomnia 
only, 23 (10.6%) reported pRBD only, and 18 (8.3%) EDS 
only. Twenty-five (11.5%) PD patients reported two types 
of sleep disturbances: 11 (5.0%) reported both EDS and 
pRBD, nine (4.1%) reported both insomnia and pRBD, and 
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five (2.3%) reported both insomnia and EDS. Three (1.4%) 
PD patients reported all three types of sleep disturbances 
(Fig. 2a).
At 5 years, 66 (30.3%) PD patients did not report any 
sleep disturbances. Eighty-five (39.0%) PD patients reported 
one sleep type of disturbance: 42 (19%) reported insom-
nia only, 24 (11.0%) reported pRBD only, and 19 (8.7%) 
reported EDS only. Fifty-one (23.4%) PD patients reported 
two types of sleep disturbances; 23 (10.6%) reported both 
insomnia and EDS; 16 (7.3%) reported both insomnia and 
pRBD; and 12 (5.5%) reported both pRBD and EDS. Sixteen 
(7.3%) PD patients reported all three types of sleep distur-
bances (Fig. 2b).
Healthy controls
At baseline, 20 (19.6%) HCs reported one type of sleep dis-
turbance, 13 (12.8%) insomnia, and 7 (6.9%) EDS). Two 
(2%) HCs reported two types of sleep disturbances (EDS and 
insomnia). At 5 years, 24 (23.5%) reported one type of sleep 
Table 1  Baseline clinical 
and demographic features of 
Parkinson’s disease (PD) and 
healthy controls (HCs)
Figures are mean ± SD unless otherwise indicated
H and Y Staging Hoehn and Yahr Staging, MDS-UPDRS Movement Disorders Society–Unified Parkinson’s 
Disease Rating Scale, NA not applicable, PIGD Postural Instability and Gait Disorder
a Chi-square test
b Mann–Whitney U test figure
Baseline information of 
PD subjects
n = 218
Baseline information of HCs
n = 102
p value
N (male/female) % (150/68)
(68.8/31.2)
(58/44); (56.9/43.1) 0.050a
Age (years) 60.9 ± 9.4
(min 33, max 84)
59.2 ± 11.1
(min 31, max 81)
0.268b
Disease duration (years) 0.59 ± 0.57 NA
Body mass index 27.1 ± 4.5
(min 18.7, max 43.8)
26.0 ± 4.3
(min 17.5, max 42.3)
0.528b
MOCA 27.1 ± 2.3 28.1 ± 1.0 0.001b
H & Y staging:  < 0.001a
 Stage 1 105 (48.1%) 1 (1.0%)
 Stage 2 111 (50.9%) 0 (0.0%)
 Stage 3 2 (0.9%) 0 (0.0%)
MDS-UPDRS
 Part I 5.35 ± 3.84 2.75 ± 2.98  < 0.001b
 Part II 5.69 ± 4.19 0.30 ± 0.79  < 0.001b
 Part III 20.9 ± 8.3 1.23 ± 2.17  < 0.001b
Use of sleep-related medica-
tions n (%)
16 (7.3%) 9(8.9%) 0.812a
Table 2  Number and percentage 
of Parkinson’s disease (PD) and 
healthy controls (HCs) reporting 
the presence of insomnia and 
excessive daytime sleepiness 
across a 5-year period with 
between-group comparisons 
made between the PD and HCs
NA not applicable
* Chi-square test. Significant differences highlighted in bold
Time point Presence of insomnia 
symptoms
Presence of excessive 
daytime sleepiness
Presence of 
REM sleep 
behavior dis-
order
PD HCs p value* PD HCs p value* PD HCs
Baseline 45 (20.6) 15 (14.7) 0.223 37 (17) 9 (8.8) 0.060 46 (21.1) NA
2 years 64 (31.5) 21 (21) 0.058 47 (23.3) 11 (11) 0.013 59 (29.1) NA
3 years 73 (34.4) 20 (20.6) 0.016 59 (27.8) 11 (11.2) 0.001 68 (32.2) NA
4 years 90 (42.7) 17 (17.4) 0.001 60 (28.6) 13 (13.3) 0.004 67 (31.9) NA
5 years 97 (44.5) 18 (17.7) 0.001 70 (32.1) 10 (9.8) 0.001 68 (31.2) NA
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disturbance, 16 (15.7%) insomnia, and 8 (7.8%) EDS, and 
two (2.0%) HCs reported two types of sleep disturbances.
Comparisons among PD subjects 
with and without sleep disturbances at 5 years
PD subjects were initially divided in two groups based on the 
absence or presence of sleep disturbance (insomnia or EDS 
or pRBD or any combination of the three sleep complaints) 
at 5 years. Statistically significant differences in LEDD at 
the 5-year follow-up were found between the two groups 
with higher median LEDD reported in subjects reporting 
sleep disturbances compared to subjects who reported no 
sleep disturbances [600 (400–800) vs. 455 (300–650) mg, 
p = 0.009].
The two groups were not statistically different in patient 
age (p = 0.655), gender (p = 0.443), MOCA (p = 0.500), 
MDS-UPDRS Part III scores (p = 0.456), medication status 
(no medications, dopamine agonists only, levodopa only, and 
both dopamine agonists and levodopa) (p = 0.114), and H & 
Y stage (p = 0.331) (Supplementary Table 3).
Pairwise group comparisons were then made between PD 
subjects who reported no sleep disturbances and PD subjects 
who reported insomnia only, EDS only, and pRBD only. PD 
subjects who reported pRBD were more likely to be male 
compared to PD subjects who reported no sleep disturbances 
(87.5% versus 65.1%, p = 0.04). PD subjects who reported 
Fig. 1  Diagram showing the percentage of subjects reporting none, one, two, or three sleep disturbances in Parkinson’s disease (PD) (a) and 
healthy controls (HCs) (b)
Fig. 2  Venn diagram showing the spectrum of sleep disturbances in the Parkinson’s disease (PD) group at baseline (a) and 5 years (b)
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insomnia had a higher LEDD compared to PD subject who 
reported no sleep disturbances (639.7 ± 353.5 mg versus 
495.2 ± 284.4 mg, p = 0.033). All other group-wise com-
parisons including age, gender, BMI, MOCA, H & Y stage, 
MDS-UPDRS Part III scores, medication status, and LEDD 
were not statistically significant (Supplementary Table 4).
Finally, PD patients were grouped into whether they 
reported none, one, two, or three types of sleep disturbances 
at 5 years. Statistically significant differences in LEDD at 
the 5-year follow-up were found between groups using the 
Kruskal–Wallis test (χ2 = 11.54, p = 0.009). Post hoc analy-
sis found that subjects reporting three types of sleep dis-
turbances had a higher median LEDD (800 mg) compared 
to subjects who reported no sleep disturbances (455 mg) 
(p = 0.006). Subjects reporting only one sleep disturbance 
with a median LEDD of 512.5 mg and subjects reporting 
two sleep disturbances only with a median LEDD of 600 mg 
were not statistically different from subjects with no sleep 
disturbances. No other statistically significant differences 
were found.
The four groups were not significantly different in patient 
age (p = 0.413), gender (p = 0.510), MOCA (p = 0.289), and 
MDS-UPDRS Part III scores (p = 0.548). No group differ-
ences in medication status (no medications, dopamine ago-
nists only, levodopa only, and both dopamine agonists and 
levodopa) were found between the patient groups using the 
Chi-square test (p = 0.562).
Discussion
Our study evaluated the longitudinal progression of three 
common sleep disturbances (EDS, insomnia, and RBD) and 
their interactions over a 5-year period in early PD. We found 
a progressive increase in the frequency of the different types 
of sleep disturbances. The greatest increase in frequency 
was observed for insomnia, followed by EDS and pRBD. 
Insomnia was also the most common sleep problem reported 
at any time over the 5-year follow-up. The percentage of 
patients with at least one type of sleep disturbance increased 
from 46% at baseline to 70% after 5 years. The percentage of 
patients with multiple sleep disturbances also increased over 
time, but remained relatively small. Interestingly, one-third 
of PD patients continued to remain free of sleep disturbances 
when assessed using our methodology. In contrast, we found 
that the frequency of sleep disturbances (EDS and insomnia) 
in HCs remained stable over time.
The novel aspect of our study is that we have assessed the 
coexistence of EDS, pRBD, and insomnia and their progres-
sion in individual patients over 5 years. In our longitudinal 
assessment, we found a progressive increase in the number 
of patients reporting multiple sleep disturbances. However, 
the proportion of these patients remained small. The low 
percentage of patients with multiple sleep problems sug-
gests that the pathophysiology of the different sleep distur-
bances in early PD might be due to different mechanisms 
that attenuate or influence the co-expression of other sleep 
disturbances.
EDS in PD patients is multifactorial, but could poten-
tially be caused by insomnia and poor sleep. However, in 
our cohort, only a minority of PD subjects had co-exist-
ing insomnia and EDS at baseline, with the proportion of 
patients with these two disturbances increasing over time but 
remaining low at 11%. Similarly, only 2% of HCs reported 
co-existing insomnia and EDS at baseline, which remained 
unchanged after 5 years. These findings would suggest that 
insomnia and EDS are not related in the majority of PD 
patients. We recently reported that EDS was associated 
with reduced postsynaptic dopaminergic receptor availabil-
ity measured with [11C]-PHNO PET, but that was not the 
case for sleep-onset and sleep-maintenance insomnia [13]. 
However, we acknowledge that EDS could potentially be 
due to another undiagnosed primary sleep disorder such as 
obstructive sleep apnoea and Restless Legs syndrome, which 
were not assessed in this study. Similarly, the presence of 
comorbid mental health problems is likely to be relevant 
in an unknown proportion of patients with sleep-related 
complaints.
It is notable that one-third of our patients continued to 
remain free of sleep complaints. Although the use of ques-
tionnaires might have under-estimated the occurrence of 
sleep disorders, cross-sectional studies using polysomnog-
raphy have also identified a proportion of patients (3.5–20%) 
free of sleep disturbances [14–16], possibly representing a 
milder disease phenotype. PD subjects with no reported 
sleep complaints after 5 years did not differ from PD sub-
jects who reported any sleep disturbance, except that higher 
LEDDs were observed in subjects who reported any sleep 
disturbance or insomnia only.
We have also evaluated the longitudinal progression of 
the individual sleep disturbances over the 5-year period. 
Only a few studies have examined the longitudinal change 
of different sleep disturbances in early PD often with 
inconsistent findings. One study performed over 2 years 
did not find any change in the reported frequencies of 
daytime somnolence, insomnia, and dream enactment in a 
cohort of 97 newly diagnosed PD patients [17]. However, 
no control population was investigated and the coexist-
ence of different sleep problems in individual patients was 
not assessed. The same cohort of patients was reassessed 
at 4-year follow-up and, while there was a significant 
increase in frequency of EDS, the frequencies of insom-
nia and dream enactment were similar to baseline [18]. In 
another study, which used a self-designed sleep question-
naire, occurrence of insomnia in general remained stable 
from baseline through a 5-year period [17–19]. Using the 
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PPMI database over a shorter duration, Simuni and col-
leagues did not find any significant increase in reported 
frequency of EDS, insomnia, and pRBD over 2 years [20], 
while Amara and colleagues reported an increased fre-
quency of EDS and pRBD over 3 years, but did not study 
insomnia [21]. Finally, two studies reported an increase 
in the frequency of pRBD in early PD cohorts [22, 23].
We found that insomnia was the most common sleep 
problem reported at any time over the 5-year follow-up. 
This finding is consistent with cross-sectional studies in 
advanced PD that also found insomnia to be the most com-
monly reported sleep disturbance [14, 24, 25]. However, 
we found that the frequency of insomnia in PD patients 
was significantly higher than in HCs only after 3 years 
of follow-up. Insomnia also had the greatest increase in 
frequency that rose steadily during the 5 years. This is 
consistent with polysomnographic studies showing pro-
gressive sleep destructuring with disease progression 
[26]. Taken together, these results would suggest that 
development of insomnia in PD mainly occurs in mid- to 
advanced stages of disease. However, our study design did 
not allow us to make the distinction between sleep-onset 
and sleep-maintenance insomnia. A previous study in early 
PD has suggested that the prevalence of sleep-maintenance 
insomnia increases over time, but that of onset insomnia 
decreases over time [19].
We also found that pRBD frequency increased from 21% 
at baseline to 31% after 5 years, which is consistent with 
findings from two previous studies in smaller cohorts of 
early PD patients [22, 23]. However, in comparison to these 
studies [22, 23], we report a slower increase in pRBD fre-
quency of approximately 2% per year. This is probably due 
to the increasing proportion of subjects treated for RBD in 
our study over time.
We then assessed the possible effects of dopamine 
replacement drugs on sleep disorders. Our findings sug-
gest that the overall impact of LEDD on the total number of 
reported sleep disorders was small. PD patients reporting 
three types of sleep disturbances had a higher median LEDD 
compared to subjects without sleep disturbances. However, 
no differences were observed in the other pairwise compari-
sons where subjects reported fewer (zero, one, or two) types 
of sleep disturbances, although there was a trend for higher 
LEDDs to be associated with increasing number of reported 
sleep disturbances. This observed trend could reflect more 
severe disease being associated with a greater number of 
sleep disturbances. However, this is also complicated by 
the use of dopamine agonists in younger patients in milder 
disease, which is associated with excessive somnolence. In 
other studies investigating isolated sleep symptoms in early 
PD, LEDDs have been reported to be higher in EDS [19] but 
not different in insomnia [19] and RBD [23].
The previous studies in early PD have not reported differ-
ences in MDS-UPDRS Part III scores in subjects reporting 
EDS [27, 28], insomnia [19], and RBD [23, 29]. Consistent 
with the previous studies, we did not find differences in age 
and number of sleep disturbances [21, 27, 28], insomnia 
[19], and RBD [23, 29].
Interestingly, despite finding a progressive increase in 
the frequency of the different types of sleep disturbances 
in our patients and, at the 5-year visit, 70% of the patients 
were complaining of sleep problems, there was only a small 
increase in the proportion of patients taking sleep medica-
tions at 5-year follow-up compared to baseline. Although it 
is possible that not all sleep complaints are severe enough 
to require medical therapy, our findings indicate that a large 
number of patients with PD do not receive the appropriate 
clinical attention for their sleep disorder.
The major strength of the study is the large number of 
well-characterized early PD subjects who were assessed at 
multiple time points. Additionally, the high retention rate 
allowed for the longitudinal analysis of sleep characteris-
tics. Thus, our findings are based on assessments that can 
be performed as part of the routine standard of care and 
realistically reflect the patients’ subjective sleep complaints 
reported in clinical settings. There are, however, a number 
of limitations. While the MDS-UPDRS sub-item 1.7 was 
previously used [6] to screen clinically relevant insomnia 
and shown to have good correlation with other insomnia 
rating scales [7], we did not perform any objective meas-
ures of EDS or RBD. Therefore, the real frequency of sleep 
symptoms and other undiagnosed primary sleep disorders 
in our patients could be under-estimated in the absence 
of polysomnography. However, we wanted to capture the 
prevalence of sleep problems with simple tools that could 
reflect the complaints reported by the patients and be used 
in routine clinical settings. There was a higher proportion 
of male subjects in the PD group relative to the HCs group, 
which could have either over-estimated or under-estimated 
the relative expression of the different sleep disturbances. In 
the general population, the male gender was associated with 
a lower reporting of insomnia complaints [30, 31] but higher 
reporting of dream enactment behaviors [32]. In the PD pop-
ulation, gender has been shown not to influence reporting 
of RBD using the RBDSQ [33], but more frequent report-
ing of EDS [27, 34, 35]. Overall, the effect of gender on 
sleep complaints could have under-estimated the frequency 
of increased insomnia complaints in the PD group relative 
to the HC group, but over-estimated the relative increased 
frequency of EDS and RBD in our cohort.
In conclusion, we present 5-year longitudinal data from 
the PPMI cohort and show that the frequency of insomnia, 
EDS, and pRBD all increase over time in early PD, with 
insomnia frequency increasing most rapidly. At the indi-
vidual level, the profile of sleep disturbances reported was 
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variable, necessitating careful clinical assessment to identify 
the underlying sleep complaints, as they have different treat-
ments. Although sleep disturbances are common, one-third 
of the PPMI cohort remained free of sleep complaints after 
7 years of disease. Finally, the small number of patients with 
multiple types of sleep disturbances suggests that the differ-
ent disturbances have different pathogenesis.
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